Sudeep Pharma (BOM:544619) Total Equity: ₹8,981 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:544619 Sudeep Pharma Ltd BOM:544619
18 GF Score
Price ₹868.55
! 5 Warning Signs
View Full Analysis

What is Sudeep Pharma Total Equity?

Sudeep Pharma BOM:544619 -1.10% 18 Total Equity is ₹8,981 Mil as of Mar. 2026. GuruFocus rates BOM:544619 with a GF Score™ of 18/100. The stock has 5 warning signs investors should review.

Sudeep Pharma's total equity for the quarter that ended in Mar. 2026 was ₹8,981 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Sudeep Pharma Total Equity Historical Data

* Premium members only.

The historical data trend for Sudeep Pharma's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sudeep Pharma Total Equity Chart

Sudeep Pharma Annual Data
Trend Mar23 Mar24 Mar25 Mar26
Total Equity
2,232.85 3,560.34 4,930.92 8,980.92

Sudeep Pharma Quarterly Data
Mar23 Mar24 Dec24 Mar25 Jun25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial 0.00 4,930.92 6,939.30 0.00 8,980.92
BOM:544619
18GF Score
Sudeep Pharma Ltd BOM:544619
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sudeep Pharma Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Sudeep Pharma's Total Equity for the fiscal year that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=11748.765-2767.847
=8,981

Sudeep Pharma's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=11748.765-2767.847
=8,981

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of ₹8,981 Mil mean?
Sudeep Pharma (BOM:544619) has a Total Equity of ₹8,981 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Sudeep Pharma and its competitors.
Is Sudeep Pharma's Total Equity too high?
Sudeep Pharma's current Total Equity is ₹8,981 Mil. Overall, Sudeep Pharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Sudeep Pharma's Total Equity compare to ZTS?
Sudeep Pharma's Total Equity of ₹8,981 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Sudeep Pharma and its competitors. Sudeep Pharma's current Total Equity is ₹8,981 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sudeep Pharma stock overvalued right now?
Sudeep Pharma (BOM:544619) has a current Total Equity of ₹8,981 Mil. The current Total Equity is ₹8,981 Mil. Sudeep Pharma's overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Sudeep Pharma (BOM:544619), the current Total Equity is ₹8,981 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sudeep Pharma Business Description

Other Exchanges SUDEEPPHRM:India
Address Gotri-Sevasi Road, 601-602, 6th floor, Sears II, East Wing, Towers - 2, Sevasi, Vadodara, GJ, IND, 391101
Sudeep Pharma Ltd is a technology led manufacturer of excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries and is dedicated to contributing to the healthcare ecosystem. The company operates in two business verticals: Pharmaceutical, food, and nutrition. It focuses on providing refined, mineral-based single ingredients essential to the pharmaceutical, food, and nutrition industries and Specialty ingredients: It pertains manufacturing of specialty ingredients using advance technology solutions. The maximum revenue is generated from the Pharmaceutical, food, and nutrition segment. Geographically, it has presence in the United States, South America, Europe, the Middle East, Africa, and Asia-Pacific.
18GF Score

Get the complete analysis for BOM:544619

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹868.55
Price